BioCentury | Dec 11, 2020
Finance

AbCellera valuation tops $15B as 2020’s IPO class nears completion

...A, a small seed round and grants. Early this year, the company’s AI-guided approach to mAb discovery...
BioCentury | Aug 12, 2020
Deals

Ligand looking to future deals around protein expression platform with Pfenex takeout

...Expression Technology, a bacteria-based protein expression platform. Ligand said the technology will complement its existing mAb discovery...
BioCentury | Jun 27, 2020
Product Development

Modeling harmony: learning from preclinical coordination of COVID-19 countermeasures

...screen on the order of a few hundred mAbs, noting that the targeted nature of mAb discovery...
BioCentury | May 20, 2020
Product Development

Vir backs cross-reactive mAb strategy with preclinical potency data

...COVID-19, VIR-7831 and VIR-7832, are based on S309. Vir Biotechnology Inc. (NASDAQ:VIR) has approached COVID-19 mAb discovery...
BioCentury | Apr 7, 2020
Politics, Policy & Law

U.K. biopharma COVID-19 fight gets closer to home with PM in ICU, death toll escalating

...see “GSK Invests $250M in Vir” ). AstraZeneca plc (LSE:AZN; NYSE:AZN), too, has launched a mAb discovery...
BioCentury | Apr 3, 2020
Product Development

COVID-19: manufacturing mAbs in patients

...was released; design and manufacturing took 25 days. Neurimmune and Ethris Neurimmune is pairing its mAb discovery...
BioCentury | Mar 14, 2020
Product Development

AbCellera, Vir find partners for COVID-19 mAb manufacturing capacity

...development of COVID-19 mAbs. The deal gives WuXi Biologics commercialization rights in Greater China. Vir’s mAb discovery...
BioCentury | Feb 25, 2020
Deals

Vir, WuXi collaborating on COVID-19 mAbs

...Tuesday a collaboration to develop and manufacture mAbs to treat COVID-19. The partnership combines Vir’s mAb discovery...
BioCentury | Feb 22, 2020
Product Development

COVID-19 mAb menagerie

...COVID-19’s ark At least five company and academic teams have disclosed use of specific mAb discovery...
...Antibodies Ltd. (TSX-V:IPA; Pink:IPATF), said Thursday it will combine its B Cell Select and DeepDisplay mAb discovery...
BioCentury | Feb 21, 2020
Politics, Policy & Law

Biopharma industry, academics push back against demands for price controls on COVID-19 countermeasures

...diseases and viral vector technologies, told BioCentury last week that the company had started COVID-19 mAb discovery...
Items per page:
1 - 10 of 35
BioCentury | Dec 11, 2020
Finance

AbCellera valuation tops $15B as 2020’s IPO class nears completion

...A, a small seed round and grants. Early this year, the company’s AI-guided approach to mAb discovery...
BioCentury | Aug 12, 2020
Deals

Ligand looking to future deals around protein expression platform with Pfenex takeout

...Expression Technology, a bacteria-based protein expression platform. Ligand said the technology will complement its existing mAb discovery...
BioCentury | Jun 27, 2020
Product Development

Modeling harmony: learning from preclinical coordination of COVID-19 countermeasures

...screen on the order of a few hundred mAbs, noting that the targeted nature of mAb discovery...
BioCentury | May 20, 2020
Product Development

Vir backs cross-reactive mAb strategy with preclinical potency data

...COVID-19, VIR-7831 and VIR-7832, are based on S309. Vir Biotechnology Inc. (NASDAQ:VIR) has approached COVID-19 mAb discovery...
BioCentury | Apr 7, 2020
Politics, Policy & Law

U.K. biopharma COVID-19 fight gets closer to home with PM in ICU, death toll escalating

...see “GSK Invests $250M in Vir” ). AstraZeneca plc (LSE:AZN; NYSE:AZN), too, has launched a mAb discovery...
BioCentury | Apr 3, 2020
Product Development

COVID-19: manufacturing mAbs in patients

...was released; design and manufacturing took 25 days. Neurimmune and Ethris Neurimmune is pairing its mAb discovery...
BioCentury | Mar 14, 2020
Product Development

AbCellera, Vir find partners for COVID-19 mAb manufacturing capacity

...development of COVID-19 mAbs. The deal gives WuXi Biologics commercialization rights in Greater China. Vir’s mAb discovery...
BioCentury | Feb 25, 2020
Deals

Vir, WuXi collaborating on COVID-19 mAbs

...Tuesday a collaboration to develop and manufacture mAbs to treat COVID-19. The partnership combines Vir’s mAb discovery...
BioCentury | Feb 22, 2020
Product Development

COVID-19 mAb menagerie

...COVID-19’s ark At least five company and academic teams have disclosed use of specific mAb discovery...
...Antibodies Ltd. (TSX-V:IPA; Pink:IPATF), said Thursday it will combine its B Cell Select and DeepDisplay mAb discovery...
BioCentury | Feb 21, 2020
Politics, Policy & Law

Biopharma industry, academics push back against demands for price controls on COVID-19 countermeasures

...diseases and viral vector technologies, told BioCentury last week that the company had started COVID-19 mAb discovery...
Items per page:
1 - 10 of 35